$CLDX

$33.55▲ +0.1% YTD

6 SEC 13D/G filings tracked · Last updated Sep 23, 2026

Filing History

CLDX ▲ +0.1% - Celldex Therapeutics, Inc.

CP $33.55▲ +0.1%Sep 23, 2026 · ThinkSabio Blog

$CLDX Morgan Stanley raised the firm's price target on Celldex to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrate…

News

CLDX ▲ +18.8% - Celldex Therapeutics, Inc.

CP $45.02▲ +18.8%Sep 22, 2026 · ThinkSabio Blog

$CLDX vol pm…

News

CLDX ▲ +18.8% - Celldex Therapeutics, Inc.

CP $45.02▲ +18.8%Sep 22, 2026 · ThinkSabio Blog

$CLDX - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary E…

News

CLDX ▼ -1.4% - Celldex Therapeutics, Inc.

CP $39.12▲ -1.4%Sep 8, 2026 · ThinkSabio Blog

$CLDX - Celldex to Present at Upcoming Investor Conference…

SEC 13D/G

CLDX - Celldex Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified

$41.16▲ 52.33%Aug 14, 2026 · ThinkSabio Blog

$CLDX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CLDX Celldex Therapeutics, Inc. : $41.16 Sector: Healthcare | Y…

SEC 13D/G

CLDX - Celldex Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified

$41.48▲ 53.52%Aug 14, 2026 · ThinkSabio Blog

$CLDX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #CLDX Celldex Therapeutics, Inc. : $41.48 Sector: Healthcare | Y…